These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 37683695)

  • 21. The Effects of Aβ
    Hsu JT; Tien CF; Yu GY; Shen S; Lee YH; Hsu PC; Wang Y; Chao PK; Tsay HJ; Shie FS
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360989
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Withanone from
    Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
    Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Repositioning of histamine H
    Ge S; Wang X; Hou Y; Lv Y; Wang C; He H
    Eur J Pharmacol; 2021 Apr; 896():173897. PubMed ID: 33497607
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Humanized COVID-19 decoy antibody effectively blocks viral entry and prevents SARS-CoV-2 infection.
    Huang KY; Lin MS; Kuo TC; Chen CL; Lin CC; Chou YC; Chao TL; Pang YH; Kao HC; Huang RS; Lin S; Chang SY; Yang PC
    EMBO Mol Med; 2021 Jan; 13(1):e12828. PubMed ID: 33159417
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2).
    Xiang Y; Wang M; Chen H; Chen L
    Biochem Pharmacol; 2021 Oct; 192():114724. PubMed ID: 34371003
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Different compounds against Angiotensin-Converting Enzyme 2 (ACE2) receptor potentially containing the infectivity of SARS-CoV-2: an in silico study.
    Shahbazi B; Mafakher L; Teimoori-Toolabi L
    J Mol Model; 2022 Mar; 28(4):82. PubMed ID: 35249180
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infection.
    Chaouat AE; Achdout H; Kol I; Berhani O; Roi G; Vitner EB; Melamed S; Politi B; Zahavy E; Brizic I; Lenac Rovis T; Alfi O; Wolf D; Jonjic S; Israely T; Mandelboim O
    PLoS Pathog; 2021 Dec; 17(12):e1010175. PubMed ID: 34929007
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SARS-CoV-2 and SARS-CoV Spike-Mediated Cell-Cell Fusion Differ in Their Requirements for Receptor Expression and Proteolytic Activation.
    Hörnich BF; Großkopf AK; Schlagowski S; Tenbusch M; Kleine-Weber H; Neipel F; Stahl-Hennig C; Hahn AS
    J Virol; 2021 Apr; 95(9):. PubMed ID: 33608407
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutations in spike protein and allele variations in ACE2 impact targeted therapy strategies against SARS-CoV-2.
    Shu CJ; Huang X; Tang HH; Mo DD; Zhou JW; Deng C
    Zool Res; 2021 Mar; 42(2):170-181. PubMed ID: 33738989
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the Cytotoxic and Antiviral Effects of Small Molecules Selected by In Silico Studies as Inhibitors of SARS-CoV-2 Cell Entry.
    Carvalhal F; Magalhães AC; Rebelo R; Palmeira A; Resende DISP; Durães F; Maia M; Xavier CPR; Pereira L; Sousa E; Correia-da-Silva M; Vasconcelos MH
    Molecules; 2023 Oct; 28(20):. PubMed ID: 37894682
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The expression of hACE2 receptor protein and its involvement in SARS-CoV-2 entry, pathogenesis, and its application as potential therapeutic target.
    Al-Zaidan L; Mestiri S; Raza A; Merhi M; Inchakalody VP; Fernandes Q; Taib N; Uddin S; Dermime S
    Tumour Biol; 2021; 43(1):177-196. PubMed ID: 34420993
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Contributions of human ACE2 and TMPRSS2 in determining host-pathogen interaction of COVID-19.
    Senapati S; Banerjee P; Bhagavatula S; Kushwaha PP; Kumar S
    J Genet; 2021; 100(1):. PubMed ID: 33707363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries.
    David AB; Diamant E; Dor E; Barnea A; Natan N; Levin L; Chapman S; Mimran LC; Epstein E; Zichel R; Torgeman A
    Molecules; 2021 May; 26(11):. PubMed ID: 34072087
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.
    Yi C; Sun X; Ye J; Ding L; Liu M; Yang Z; Lu X; Zhang Y; Ma L; Gu W; Qu A; Xu J; Shi Z; Ling Z; Sun B
    Cell Mol Immunol; 2020 Jun; 17(6):621-630. PubMed ID: 32415260
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The histamine receptor H1 acts as an alternative receptor for SARS-CoV-2.
    Yu F; Liu X; Ou H; Li X; Liu R; Lv X; Xiao S; Hu M; Liang T; Chen T; Wei X; Zhang Z; Liu S; Liu H; Zhu Y; Liu G; Tu T; Li P; Zhang H; Pan T; Ma X
    mBio; 2024 Aug; 15(8):e0108824. PubMed ID: 38953634
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of the Role of N-Linked Glycosylation in Cell Surface Expression, Function, and Binding Properties of SARS-CoV-2 Receptor ACE2.
    Rowland R; Brandariz-Nuñez A
    Microbiol Spectr; 2021 Oct; 9(2):e0119921. PubMed ID: 34494876
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Virtual screening and molecular dynamics study of approved drugs as inhibitors of spike protein S1 domain and ACE2 interaction in SARS-CoV-2.
    Prajapat M; Shekhar N; Sarma P; Avti P; Singh S; Kaur H; Bhattacharyya A; Kumar S; Sharma S; Prakash A; Medhi B
    J Mol Graph Model; 2020 Dec; 101():107716. PubMed ID: 32866780
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
    Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    Elife; 2020 Oct; 9():. PubMed ID: 33112236
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Salvianolic acid B and its magnesium salt inhibit SARS-CoV-2 infection of Vero-E6 cells by blocking spike protein-mediated membrane fusion].
    Yang C; Cheng C; Wang J; Chen K; Zhan J; Pan X; Xu X; Xu W; Liu S
    Nan Fang Yi Ke Da Xue Xue Bao; 2021 Apr; 41(4):475-482. PubMed ID: 33963705
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A highly sensitive bead-based flow cytometric competitive binding assay to detect SARS-CoV-2 neutralizing antibody activity.
    Yao X; Zhang Z; Mei Q; Li S; Xing L; Long Y; Zhang D; Wang J; Wang X; Xie B; Yang B; Gao Y; Wu C; Meng Q
    Front Immunol; 2022; 13():1041860. PubMed ID: 36532082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.